Cigar Association Opposes FDA's Flavored Cigar Ban Proposal

Aug.09.2022
Cigar Association Opposes FDA's Flavored Cigar Ban Proposal
The CAA opposes the FDA's proposed ban on flavored cigars, citing that underage use is at historically low levels.

Source: Andrii


The Cigar Association of America (CAA) has submitted a comment opposing the proposed ban on flavored cigars by the US Food and Drug Administration (FDA), citing the FDA's data that shows underage use of flavored cigars (the main reason for the proposal) is at a historic low and has been steadily decreasing since the year before last.


This clearly indicates that the FDA is proposing solutions to address the issue," said David M. Ozgo, president of the CAA, in a statement. "The use of flavored cigars by minors is insignificant. This is a blatant example of an industry targeting legally-aged adults with their products.


A commentary has highlighted that one of the primary objectives of the Tobacco Control Act, which grants the FDA the authority to regulate tobacco, is to allow the sale of tobacco products to adults while taking measures to ensure that they are not sold or obtained by underage buyers. The current historically low levels of youth use indicate the effectiveness of existing measures.


According to the CAA, government evidence indicates that the use of cigars by young people is so low that it is almost negligible. When the FDA first sought regulatory authority over certain tobacco products in 1996, the only survey tracking adolescent use of cigars in 1997, the National Survey on Drug Use and Health (NSDUH), showed a recent 30-day youth use rate of 5%. In 2020, NSDUH tracked the proportion of adolescents who used cigars in the past 30 days to be 0.8%.


The commentary from the CAA emphasized the latest population assessment data from the government's Tobacco and Health Survey (PATH), which shows an overall decrease in the proportion of teenagers using cigars in the past 30 days to 0.75%, with the proportion of teenagers using flavored cigars being only around 0.29%.


In summary, the use of flavored cigars among teenagers has continued to decline to almost immeasurable levels, said Ozgo in the submitted comment. "The FDA claims that flavored cigars will attract young people. If this is true, we expect flavored cigars to make up the majority of cigar use among teenagers," the comment added.


But government data clearly indicates that the usage of flavored cigars among teenagers is minimal and decreasing further," stated Ozgo.


The comment also points out that the proposed ban lacks scientific basis, but will have devastating economic consequences. Many small businesses, typically those owned by minorities, will be negatively impacted as well as various cigar manufacturers, suppliers, and producers from countries like the Dominican Republic and Honduras.


Furthermore, comments from the CAA have reiterated that the FDA has not shown any differentiated impact on health caused by flavored cigars, and banning them may lead to the development of an unregulated illegal market for flavored cigars. Products produced and sold illegally often contain dangerous additives.


Statement:


This article is compiled from third-party information and is intended for communication and learning within the industry.


This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The translation of this article is solely for industry sharing and research purposes.


Due to limitations in the level of translation, the translated article may not fully capture the intended meaning of the original. Therefore, it is recommended to refer to the original article for accuracy.


2FIRSTS maintains full alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign related statements and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
BAT’s Velo Study Finds 61% of Nicotine Users Feel More Comfortable Expressing Themselves When Others Do the Same
BAT’s Velo Study Finds 61% of Nicotine Users Feel More Comfortable Expressing Themselves When Others Do the Same
British American Tobacco’s (BAT) nicotine pouch brand Velo has released a global consumer study and launched its “Echoes of Tomorrowland” campaign with electronic music festival brand Tomorrowland. The research surveyed 2,009 nicotine users across the UK, Spain, Pakistan, Poland and Austria. Velo said 61% of respondents feel more comfortable expressing themselves when they see others doing the same, while 39% said building meaningful connections becomes harder with age. The campaign reflects how nicotine pouch brands are increasingly using music, communities and lifestyle marketing to build consumer engagement.
Aug.10
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
2Firsts On-Site | CTIHK Showcases Nicotine Pouches, Heated Tobacco and Chinese Cigars at InterTabac 2026
At InterTabac 2026 in Dortmund, China Tobacco International (HK) Company Limited (CTIHK) is exhibiting across two separate booths in Hall 5 and Hall 4. Products observed by 2Firsts include heated tobacco products, nicotine pouches, Chinese cigars and tobacco leaf. Nicotine pouch products on display include TOOP, Shuangxi and Ashima.
Market
Sep.16
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana's Alcohol and Tobacco Commission (ATC) ordered tobacco certificate holders in September to remove certain vaping products marketed under Elf Bar, Lost Mary, MR FOG, iJOY and other brands from inventory under the state's foreign-adversary product law. The agency later listed 257 MR FOG products and 77 Lost Mary product entries as lawful for sale. The Lost Mary revision expressly stated that compliance evidence had been received for 20 additional products. 2Firsts compliance expert Kurt said potential filings could include e-liquid and ingredient-origin records, U.S. nicotine-analog supply-chain documentation and FDA premarket application status.
Regulations
Oct.08
 PMI Opens Generative AI Center in Portugal to Support Global Operations
PMI Opens Generative AI Center in Portugal to Support Global Operations
According to information released by Portugal’s Trade & Investment Agency (AICEP) in July 2026, Philip Morris International (PMI) has established a global Generative Artificial Intelligence Factory (GenAI Factory) at its Portuguese subsidiary Tabaqueira. The center will support PMI’s global operations by developing and deploying AI solutions focused on industrial process optimization, data analytics, operational automation and AI application development. The initiative strengthens Portugal’s role in PMI’s global technology and innovation network.
Aug.27